The INCATE Selection Committee selected the new 4 ventures for Stage I support. Meet the new additions to the INCATE family:

Arvalus Therapeutics – Arvalus is pioneering a next-generation live biotherapeutic product (LBP) engineered to precisely target and eradicate multi-drug-resistant and pathogenic bacteria from the gut.

mycoBiologics – mycoBiologics is developing patient-derived human monoclonal antibodies as new, safe and more effective anti-infective drugs.

PhalconBio – PhalconBio transforms bacteriophage therapy through engineering to deliver the next generation of precision antimicrobials.

Alterbiotix – First-in-class peptide drug candidates as a novel intervention against Streptococcus pneumoniae.

Information on the other companies selected in previous stage I applications are on the portfolio page.